Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Tyco chairman characterized Mallinckrodt's imaging, respiratory and analgesic businesses as 'strong platforms for future acquisitions and licensing…
Combination would make Tyco Healthcare the second-largest medical device manufacturer worldwide and the leader in respiratory care and bulk analgesic…
FTC required divestiture of overlapping endotracheal and laryngectomy tube product lines to preserve competition; consent order cleared the merger to close.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Tyco International acquired Mallinckrodt in a stock-swap valued at ~$4.2B ($47.50/share). Mallinckrodt brought medical imaging, respiratory care, and analgesic pharmaceuticals businesses with FY1999 revenues of $2.6B. FTC settlement preserved competition in endotracheal tubes. Closed Oct 2000.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Tyco International Ltd. / Mallinckrodt plc (this deal) | 2000 | $4.2B | 24 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Madison Dearborn Partners / Ikaria, Inc. | 2013 | $1.6B | 85 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 2025 | $12.0B | 65 |
← Browse all deals · How we score deals
More: 2000 deals · Respiratory deals